Arcutis Biotherapeutics Inc (ARQT) concluded trading on Wednesday at a closing price of $16.60, with 5.37 million shares of worth about $89.11 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 78.49% during that period and on April 03, 2025 the price saw a gain of about 10.81%. Currently the company’s common shares owned by public are about 117.85M shares, out of which, 104.39M shares are available for trading.
Stock saw a price change of 0.79% in past 5 days and over the past one month there was a price change of 23.88%. Year-to-date (YTD), ARQT shares are showing a performance of 19.17% which increased to 71.49% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.99 but also hit the highest price of $17.75 during that period. The average intraday trading volume for Arcutis Biotherapeutics Inc shares is 2.33 million. The stock is currently trading 4.98% above its 20-day simple moving average (SMA20), while that difference is up 17.27% for SMA50 and it goes to 44.50% higher than SMA200.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) currently have 117.85M outstanding shares and institutions hold larger chunk of about 102.26% of that.
The stock has a current market capitalization of $1.97B and its 3Y-monthly beta is at 1.87. It has posted earnings per share of -$1.16 in the same period. It has Quick Ratio of 3.97 while making debt-to-equity ratio of 0.70. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ARQT, volatility over the week remained 8.82% while standing at 8.01% over the month.
Stock’s fiscal year EPS is expected to rise by 49.98% while it is estimated to increase by 150.90% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on December 30, 2024 offering a Buy rating for the stock and assigned a target price of $19 to it. Coverage by Jefferies stated Arcutis Biotherapeutics Inc (ARQT) stock as a Buy in their note to investors on August 28, 2024, suggesting a price target of $15 for the stock. On January 03, 2024, Mizuho Upgrade their recommendations, while on October 26, 2023, Mizuho Downgrade their ratings for the stock with a price target of $4. Stock get a Neutral rating from Goldman on October 13, 2023.
